Roivant Sciences announced that it has entered into a collaboration with Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) to facilitate the out-licensing of investigational medicines. Under the terms of the agreement, Roivant will have the option to obtain exclusive licenses for certain development programs from Daiichi Sankyo on prespecified terms contingent on phase of development (see also Roivant Sciences).
Daiichi Sankyo has a wide range of compounds in development. Medicines that Roivant opts to license will be developed by new subsidiary companies within the Roivant family.
“It has been an honor and a pleasure for us to work with the entire Daiichi Sankyo team in the course of creating this partnership. I hope this can be a model for platform collaborations between Roivant and other innovative biopharmaceutical companies in the future,” said Dr. Mayukh Sukhatme, President of Roivant Pharma. “We look forward to accelerating the development of promising medicines from the impressive R&D engine at Daiichi Sankyo in the months and years ahead.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.